Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00691808 | Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment | PHASE2 | COMPLETED | 103 | — | — | Feb 1, 2008 | - | Mar 3, 2010 | 2 | Netherlands |
An adverse event includes any noxious, pathological, or unintended change in anatomical, physiological, or metabolic functions as indicated by physical signs or symptoms occurring in any phase of the clinical study whether or not associated with the study medication and whether or not considered related to study medication.
Subjects were considered compliant if they had taken \>70% of possible doses of the study drug.
| Arm | Type | Description |
|---|---|---|
| High Dose | EXPERIMENTAL | - |
| Low Dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| LX6171 High Dose | DRUG | A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time. |
| LX6171 Low Dose | DRUG | A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time. |
| Placebo | DRUG | Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time. |
Inclusion Criteria: * Males and females aged 60-80 years old. * Complaints of memory loss in everyday life * Non-smokers or very light smokers (no more than 10 cigarettes/day) * Negative urine screen for drugs of abuse * Ability to provide written informed consent Exclusion Criteria: * History or...